Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of DDO-3055 in Healthy Volunteers and CKD Patients
NCT03976115Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DDO-3055 in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Hengrui. Primary endpoint: Adverse Events and Serious Adverse Events up to 14 days. Started Jul 2019; status: completed.
02
Drugs
DDO-3055
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03976115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976115.